Current status of urinary cytology in the evaluation of bladder neoplasms.
about
Conventional liquid-based techniques versus Cytyc Thinprep processing of urinary samples: a qualitative approachUrine-based assays for the detection of bladder cancer.ProEx C as Diagnostic Marker for Detection of Urothelial Carcinoma in Urinary Samples: A ReviewEarly detection of urothelial premalignant lesions using hexaminolevulinate fluorescence cystoscopy in high risk patients.Detecting recurrent bladder cancer: new methods and biomarkers.Suspicious urine cytology (class III) in patients with bladder cancer: should it be considered as negative or positive?p53 immunodetection of liquid-based processed urinary samples helps to identify bladder tumours with a higher risk of progression.Bladder cancer detection and monitoring: assessment of urine- and blood-based marker testsUtility of serial urinary cytology in the initial evaluation of the patient with microscopic hematuriaDiagnosis of urothelial carcinoma from urine.Cytological and morphometric study of urinary epithelial cells with histopathological correlation.Urine cytopathology: challenges, pitfalls, and mimics.Urinary biomarkers of bladder cancer: an update and future perspectives.Overexpression of CK20, MAP3K8 and EIF5A correlates with poor prognosis in early-onset colorectal cancer patients.p16/Ki-67 dual labeling and urinary cytology results according to the New Paris System for Reporting Urinary Cytology: Impact of extended follow-up.Methylation markers for urine-based detection of bladder cancer: the next generation of urinary markers for diagnosis and surveillance of bladder cancer.Modification of The Paris System for urinary tract washing specimens using diagnostic cytological features.Digital image analysis supports a nuclear-to-cytoplasmic ratio cutoff value of 0.5 for atypical urothelial cells.A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results.Pathology of transitional cell carcinoma of the bladder and its clinical implications.Cost efficiency analysis of modern cytocentrifugation methods versus liquid based (Cytyc Thinprep) processing of urinary samples.Cytomorphological effects of mitomycin C on urothelial cells: eosinophils may be clue to the drug-induced changesRole of 5-aminolevulinic acid in the detection of urothelial premalignant lesions.Needle aspiration cytology of metastatic high-grade transitional-cell carcinomas of the urinary tract.Neural network-based digitized cell image diagnosis of bladder wash cytology.Diagnostic value of a urine-based tumor marker for screening lower urinary tract in low-risk patients with asymptomatic microscopic hematuria.Assessment of DNA flow cytometry as a surrogate end point biomarker in a bladder cancer chemoprevention trial.p16(INK4a) /Ki-67 dual labelling as a marker for the presence of high-grade cancer cells or disease progression in urinary cytopathology.Comparison of the sensitivity and specificity of urine cytology, urinary nuclear matrix protein-22 and multitarget fluorescence in situ hybridization assay in the detection of bladder cancer
P2860
Q24813961-1715D069-27E4-46D9-A9B7-D43C35101CEEQ33643957-46E2ABBF-7F6B-4E1C-AEF3-095FCA8D8E1CQ33820634-FF168394-AC57-435A-8D82-F1A3E8CE1C6AQ34372378-6BC6D978-CBB7-48A1-90F3-85F080EA28C5Q34569204-E8222E25-E252-4407-B20D-76FAD3FE129AQ34803069-B1D8F7A4-E6F6-401F-8E72-98D4EA759AACQ36615080-8A9D1F6C-486E-43C7-86C2-847BE3E64C53Q36770389-470198D8-22FB-4BAB-949D-235D00EE7921Q37362451-7AD44B41-FC45-4542-9CB7-472DBDD4F468Q37507532-521B0F28-4195-4197-A453-F9887F1A9135Q37734960-34AB987E-9C1C-4807-B5D7-76A3132859DAQ37895219-0CC21FB6-AF82-4AB7-AED0-F5EB751107C5Q38138607-860A7602-6A2B-4EF3-A645-A40F0E2D8246Q38318476-69111AC4-6E01-468A-A29D-B6A512563E5CQ38375231-96185E33-B06A-4A5B-B26B-0E128CEB8EA8Q38566949-6AE81E9E-B168-42E2-B375-9D5CAD533BD5Q40080052-202C5C86-7B1C-488E-B45C-874EDB2B3C98Q40476072-B590FD30-244F-49E2-AFCD-DA0DD1E1D351Q40654070-6BEEDA77-3E5D-42BB-A2AC-0095D46E6E0AQ41564500-A2021259-39EC-468A-90AF-0A062229F818Q41928576-05D04AD9-1860-493B-8852-5D942F6D1DDEQ41973294-58683D31-CE3F-4B47-9F14-2998F301377FQ44128410-11323FFE-0C14-4A63-8004-EA314D2DB454Q47975321-A7C8EE8E-18A7-446F-BDE8-B3E97FFB564EQ48553141-B08E1D76-0E9F-42BB-9679-A0F481BB7EBCQ51453214-4D66F6E1-BC12-4435-AE98-B6C64EE8F8E1Q53415229-90C8603A-5443-428F-8C94-665DB11D4271Q54481739-205E99CA-CD69-4984-BD56-1020FD49B7FAQ57729033-648C47C4-3A53-49E7-8157-BB47954FF925
P2860
Current status of urinary cytology in the evaluation of bladder neoplasms.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Current status of urinary cytology in the evaluation of bladder neoplasms.
@en
Current status of urinary cytology in the evaluation of bladder neoplasms.
@nl
type
label
Current status of urinary cytology in the evaluation of bladder neoplasms.
@en
Current status of urinary cytology in the evaluation of bladder neoplasms.
@nl
prefLabel
Current status of urinary cytology in the evaluation of bladder neoplasms.
@en
Current status of urinary cytology in the evaluation of bladder neoplasms.
@nl
P1433
P1476
Current status of urinary cytology in the evaluation of bladder neoplasms.
@en
P2093
P304
P356
10.1016/0046-8177(90)90171-Z
P407
P577
1990-09-01T00:00:00Z